Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial.
- DOI
- 10.3389/fphar.2022.1020123
- Published
- 2022
- Container
- Frontiers in pharmacology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fphar.2022.1020123,
title = {Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial.},
author = {Jain MK and De Lemos JA and McGuire DK and Ayers C and Eitson JL and Sanchez CL and Kamel D and Meisner JA and Thomas EV and Hegde AA and Mocherla S and Strebe JK and Li X and Williams NS and Xing C and Ahmed MS and Wang P and Sadek HA and Schoggins JW},
year = {2022},
journal = {Frontiers in pharmacology},
doi = {10.3389/fphar.2022.1020123},
url = {https://doi.org/10.3389/fphar.2022.1020123}
}RIS
TY - JOUR TI - Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial. AU - Jain MK AU - De Lemos JA AU - McGuire DK AU - Ayers C AU - Eitson JL AU - Sanchez CL AU - Kamel D AU - Meisner JA AU - Thomas EV AU - Hegde AA AU - Mocherla S AU - Strebe JK AU - Li X AU - Williams NS AU - Xing C AU - Ahmed MS AU - Wang P AU - Sadek HA AU - Schoggins JW PY - 2022 JO - Frontiers in pharmacology DO - 10.3389/fphar.2022.1020123 UR - https://doi.org/10.3389/fphar.2022.1020123 ER -
APA
MK, J., JA, D. L., DK, M., C, A., JL, E., CL, S., D, K., JA, M., EV, T., AA, H., S, M., JK, S., X, L., NS, W., C, X., MS, A., P, W., HA, S., & JW, S. (2022). Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2022.1020123
Source records
- pubmed · retrieved 2026-09-26T03:41:35.816Z